Coherus BioSciences (CHRS -2.9%) slips in average volume in apparent reaction to a district court ruling on two Enbrel patents favorable to Amgen. Novartis unit Sandoz challenged the validity of the patents in an effort to market a biosimilar to the tumor necrosis factor blocker.
Coherus is also developing a biosimilar to Enbrel, CHS-0214.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.